JPMorgan analyst Lilia-Celine Lozada raised the firm’s price target on AtriCure (ATRC) to $51 from $40 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect the Q4 pre-announcement and 2025 guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- Atricure, Inc. (ATRC) Q4 Earnings Cheat Sheet
- AtriCure price target raised to $51 from $40 at Needham
- AtriCure sees FY25 revenue $517M-$527M, consensus $522.81M
- AtriCure reports preliminary Q4 revenue $124.3M, consensus $119.85M
- AtriCure ups FY24 revenue view to $465.3M from $459M-$462M, consensus $460.89M